Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 63

recruiting
3 967
countries
28
conditions
2 124

10 514 trials match your criteria

A study to evaluate the safety and how pivekimab sunirine works in children with relapsed or refractory acute myeloid leukemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Pivekimab Sunirine

Bladder cancer

Recruiting

A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide

Contraception

Recruiting

Contraception study in women: comparing oral drospirenone‑only, drospirenone + ethinylestradiol, and drospirenone + estetrol tablets

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · Healthy volunteers
  • Substances:Drospirenone

Carboplatin‑based drug combination for advanced non‑small cell lung cancer patients with interstitial lung disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Crohn's disease

Recruiting

One-Year Effectiveness Study of Guselkumab in Adults with Crohn’s Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Guselkumab

Back pain

Recruiting

Efficacy and tolerability of diclofenac potassium + thiocolchicoside versus diclofenac potassium in patients with acute severe low back pain

Registered drug
Countries:CyprusCyprus
  • Participants:18–64 years · 65+ years
  • Substances:Diclofenac potassium

Optimizing fludarabine phosphate exposure to improve event‑free survival in children and young adults with B‑cell acute lymphoblastic leukemia receiving CAR‑T therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Fludarabine Phosphate

Neoplasm malignant+1

Recruiting

Anti‑PD1 Therapy with pembrolizumab and cemiplimab in first‑line advanced non‑small cell lung cancer patients with high PD‑L1 expression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab

Neoplasm malignant+1

Recruiting

A Phase I/II Study of GVV858 Alone or in Drug Combination for Patients with Advanced Hormone Receptor‑Positive, HER2‑Negative Breast Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant

Glofitamab plus drug combination for relapsed/refractory large B‑cell lymphoma in high‑risk second‑line patients eligible for CAR‑T therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab

Long‑Term Safety and Efficacy of Infigratinib in Children with Hypochondroplasia

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Infigratinib
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.